5-Bromoindole-2-carboxylic acid, CAS 7254-19-5, molecular formula C₉H₆BrNO₂, molecular weight 240.05 g/mol, is released as a pharmaceutical-grade API intermediate for tablet, capsule, granule, oral, and injectable manufacturing. The product descriptor “Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable” refers to a controlled chemical entity supplied in multiple release configurations rather than a single set of limits suitable for every dosage form. The C-2 carboxyl group and the C-5 bromo substituent are located on different parts of the indole ring, giving two independent reactive centers: the carboxylic acid for amide, ester, or hydrazide formation, and the aryl bromide for Suzuki–Miyaura, Heck, or Buchwald–Hartwig cross-coupling. Because no harmonized pharmacopoeial monograph exists specifically for 5-bromoindole-2-carboxylic acid, batch release is usually assembled from Ph Eur 2034, Ph Eur 5.4, ICH Q3C, and ICH Q3D requirements. The final drug product manufacturer must verify that the certificate of analysis supports the intended route of administration and dosage form.

For oral solid-dosage manufacturing, the material is a white to off-white crystalline powder with particle size, loss on drying, related substances, and residual solvents controlled for direct compression, dry granulation, wet granulation, and capsule filling. For injectable use, the same chemical backbone is supplied with more restrictive microbial, endotoxin, elemental impurity, and related-substance limits. An oral grade may be acceptable for tablet and capsule processing with total related substances ≤ 1.0%, while an injectable grade is commonly controlled to total related substances ≤ 0.5% because parenteral products have a lower tolerance for unqualified impurities under ICH Q3B.

The main quality risk in tablet and capsule use is content uniformity failure caused by particle size segregation. A batch with D90 above 250 µm can segregate from fine excipients during hopper discharge on a rotary press. The same batch milled by spiral jet mill to D90 ≤ 45 µm may become cohesive and electrostatically charged. Release testing therefore includes particle size by laser diffraction according to ISO 13320:2020, loss on drying by USP 731, and bulk and tapped density by USP 616. Powder is considered suitable for direct compression when the calculated Carr index is below 25; values between 26 and 30 require 0.25–0.50 wt% colloidal silicon dioxide NF to maintain adequate flow.

In commercial material codes, oral and injectable grades are typically distinguished by a suffix that imposes endotoxin, bioburden, and residual solvent requirements. The exact model code is manufacturer-specific and must be defined in the quality agreement. A statement that the material is “pharmaceutical grade” does not by itself ensure suitability for injection; injectable suitability depends on batch-specific data for bacterial endotoxins, subvisible particulates, elemental impurities, and process residuals.

What Limits the Suitability of Unmilled 5-Bromoindole-2-carboxylic Acid for Low-Dose Tablets?

For low-dose tablets containing 1–5 wt% API, unmilled material with D90 above 250 µm may produce unacceptable content uniformity. Content uniformity is evaluated by USP 905; an acceptance value ≤ 15 is required for most tablets. If the API segregates, the relative standard deviation of the blend increases and the acceptance value rises. Jet milling to D90 ≤ 45 µm removes large crystals but increases surface area and static charge. Blends with Carr index above 30 are prone to die-fill variation on rotary tablet presses operating at 60–80 rpm. To compensate, 0.5 wt% colloidal silicon dioxide NF is pre-blended with the API before the main excipient addition. Compression is performed with 10 mm round flat-faced bevel-edged punches at compression pressures of 80–160 MPa. Loss on drying is maintained ≤ 0.5% to reduce punch filming and capping. Published data for this specific compound in direct-compression matrices are limited; the above processing values are equipment-dependent and require pilot-scale confirmation.

Batch-to-batch variation in API moisture above 0.3% shifts the wet-granulation endpoint if the granulating fluid volume is fixed. In high-shear or low-shear granulation, the granulating fluid is added until a defined power-consumption or visual endpoint is reached. A 20–30% w/w water addition is typical for microcrystalline cellulose–lactose systems, but the brominated aromatic acid may dissolve slowly in aqueous binder solution, so the binder is pre-dissolved before addition. The granulated mass is dried in a fluid-bed dryer with inlet air at 50–60°C until loss on drying is ≤ 2.0%, then screened through an 0.8 mm aperture to remove oversized granules. Granule flow and bulk density are checked before tablet compression or capsule filling; low granule density can destabilize the powder bed height in the feed frame or dosator hopper.

In capsule filling on an intermittent-motion dosator machine, the powder or granule bed must retain a stable plug. If the API is micronized to D90 ≤ 20 µm, it may fluidize in the hopper and reduce fill weight consistency. Addition of 0.5–1.0 wt% sodium stearyl fumarate NF or a low-moisture starch NF improves plug formation. Capsule fill weight is monitored by in-process check weighers set to reject capsules outside ± 3% of target. Process failures are commonly attributed to static charge or ambient relative humidity above 55%.

Injectable Processing and Endotoxin-Control Boundaries

Injectable use requires conversion of the free acid to a soluble salt or suspension. The free acid has pH-dependent aqueous solubility; dissolution is widely performed in 0.05 M phosphate buffer pH 7.0–7.4 with stoichiometric sodium bicarbonate or sodium hydroxide to form the carboxylate salt. The resulting solution is not sterile and must be passed through a 0.22 µm sterilizing-grade filter under aseptic conditions. Because brominated aromatic compounds can adsorb to hydrophobic PVDF or polyethersulfone membranes, filter recovery studies are required. A filter adsorption loss greater than 2% of label claim requires a more hydrophilic membrane, a preflush, or process adjustment. Terminal sterilization is evaluated only if the API shows acceptable solution stability; otherwise aseptic filtration is used.

For a general parenteral product, USP 85 sets the endotoxin limit as K/M, with K = 5 EU/kg body weight; for intrathecal injection, K = 0.2 EU/kg. If the maximum dose is 100 mg and the product is administered as a single daily injection to a 70 kg patient, the calculated API endotoxin limit is 3.5 EU/mg. Final injectables must also comply with subvisible particulate limits in USP 788. For small-volume parenterals, the commonly cited limits are 6000 particles per container at ≥ 10 µm and 600 particles per container at ≥ 25 µm. The dry API is not expected to meet USP 788 as a powder; the test applies to the finished liquid or reconstituted product.

Published data for terminal autoclaving of the dry solid are limited; the operational boundary is to use 25–40°C for dissolution and to avoid pH above 10 for prolonged periods because indole carboxylates can undergo degradation. The free carboxylic acid is incompatible with strong bases, strong oxidizing agents, and primary amines under heating unless salt formation or amidation is intended. In a lyophilized injectable, the bulk solution should be held at 2–8°C for no more than 24 h before filling if the stability data support that hold time. The lyophilized cake should have residual moisture ≤ 2.0% and the reconstituted solution must comply with the same endotoxin and particulate limits as the original liquid.

When Biocatalytic Synthesis Replaces Conventional Electrophilic Bromination

In conventional chemical synthesis, bromination of indole-2-carboxylic acid with bromine or N-bromosuccinimide may produce C-3, C-5, C-6 brominated derivatives and dibrominated impurities. A biocatalytic route using a regioselective halogenase may direct bromination to C-5 and reduce certain positional isomers, but it introduces aqueous protein, polysaccharide, and DNA burdens. If the manufacturer claims a biocatalytic process, residual host cell protein should be reported by a validated immunoassay and residual DNA should be reported by a quantitative method with limits consistent with the final dose. Without these data, the injectable grade cannot be assumed low-protein or low-endotoxin simply because the route is biocatalytic.

Residual solvent profiles also differ. The biocatalytic step often operates in an aqueous buffer, followed by solvent extraction. If ethyl acetate or dichloromethane is used for extraction, the solvent must be cleared to ICH Q3C limits. Dichloromethane is Class 2 with a permitted daily exposure of 6.0 mg/day and a concentration limit of 600 ppm; methanol is ≤ 3000 ppm; acetone is ≤ 5000 ppm. If palladium-catalyzed coupling is used later to prepare the API or its downstream derivatives, palladium content must be measured by USP 233 and controlled to the ICH Q3D parenteral permitted daily exposure of 10 µg/day for an injectable. The biocatalytic route does not automatically eliminate heavy metals; only the certificate of analysis can document compliance.

The release specification matrix for oral and injectable grades is summarized below. Limits are representative and must be justified against the final product dose and dosing frequency.

5-Bromoindole-2-carboxylic Acid Differs From Indole-2-carboxylic Acid and 5-Bromoindole-3-carboxylic Acid

Indole-2-carboxylic acid has the same C-2 carboxyl group but no bromine; its molecular weight is 161.16 g/mol. The introduction of bromine at C-5 increases molecular weight to 240.05 g/mol and changes polarity, lipophilicity, and cross-coupling capacity. The 5-bromo derivative is selected when a stable aryl halide is required for C–C bond formation, while indole-2-carboxylic acid is used when the unsubstituted ring is acceptable. The C-2 acid also differs from 5-bromoindole-3-carboxylic acid, which has the same formula and molecular weight but places the carboxyl group at C-3. That change alters the reactivity of the pyrrole ring, the site of decarboxylative coupling, and the final amide series obtained after condensation. Although the two isomers share the formula C₉H₆BrNO₂, they are not interchangeable in drug substance synthesis.

The positional impurity profile is the practical differentiating criterion. The 5-bromo product is controlled for the 4-bromo, 6-bromo, and 7-bromo regioisomers and for dibromo impurities. Conventional bromination may produce higher levels of the 6-bromo isomer; a biocatalytic route may reduce the 6-bromo isomer but requires demonstration that the C-3 bromo derivative is not formed. The following table summarizes structural and functional differentiation.